ACTIV-2 Trial (LY-CoV555) Comes to Jasper, AL’s Jasper Summit Research

Oct 16, 2020 | Alabama, COVID-19, LY-CoV555, Monoclonal Antibody, News

ACTIV-2 Trial (LY-CoV555) Comes to Jasper AL’s Jasper Summit Research

The ACTIVE-2 clinical trial comes to north central Alabama at Jasper Summit Research. Now residents in and around Jasper, AL, infected with COVID-19 can potentially access advanced monoclonal antibody therapies. Jasper Summit Research will be one of over 30 facilities across the nation, and one of the initial sites, to offer the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial. Conducted by the AIDS Clinical Trials Group (ACTG), this clinical trial is designed to help treat COVID-19 before advanced treatment intervention could be required.

Recently, Nicole Smith writing for the Mountain Eagle introduced this part of Alabama to ACTIVE-2, a clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Apparently, according to this local account, the NIH approached Jasper Summit Research about trial participation.

ACTIVE-2 Trial

On Aug. 4TrialSite introduced ACTIV-2 as a NIAID-backed study involving Lilly’s LY-CoV555 monoclonal antibody investigational product. The) investigates the effect of one or two drugs on a medical condition and involves Lilly. This Phase 2/3 trial seeks 2000 patients and the estimated primary completion date is November 2020.

According to Principal Investigator Dr. Jan Westerman, “This study aims to develop a treatment that can prevent people with COVID-19 from developing advanced disease that requires hospitalization,” Westerman said in a press release. “While people with COVID-19 may start off with just a few minor symptoms, they can rapidly become very ill, and this is true of both young and older people. People living in the Jasper/Walker County area who have recently been diagnosed with COVID-19 and are not hospitalized have the opportunity to make a huge contribution by participating in this study.”

Ms. Smith notified Alabama residents that to qualify for this trial one must be tested positive for SARS-CoV-2 in an outpatient setting within seven days of enrolling in the trial. They must also have started experiencing symptoms within 10 days of enrollment.

Principal Investigator

Dr. of Jasper, AL, will serve as principal investigator at the trial at Jasper Summit Research. A Board Certified Physician in sleep, critical care, pulmonary and internal medicine, Dr. Westerman attended University of Alabama School of Medicine, graduating in 1985. He completed his residency at USAF Medical Center Keesler in 1988 and his fellowship at University of North Carolina Hospital in 1991.

Investigational Product

Note, this study involves LY-CoV555 the monoclonal antibody developed by Lilly in partnership with AbCellera and NIAID.  with the FDA.

ACTIV-3 Safety Pause for Lilly Combination

Part of another study, ACTIV-3, Lilly’s combination product (which involves LY-CoV555 and a monoclonal antibody licensed by a Chinese firm) has been placed on a right now. 



Submit a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. .

Pin It on Pinterest